Good Products, Closed Doors: The Regulatory Market Entry Crisis Facing U.S. Pharmaceutical and Biomedical SMEs

References

[1] Junaid SB, Imam AA, Balogun AO, De Silva LC, Surakat YA, Kumar G, et al. Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey. Healthcare (Basel). 2022 Oct 3;10(10):1940. doi:10.3390/healthcare10101940 PubMed PMID: 36292387; PubMed Central PMCID: PMC9601636.

[2] Peralta G, Sánchez B. Driving health transformation: big pharma’s innovation labs revolution. Health Res Policy Syst. 2025 Oct 23; 23:138. doi:10.1186/s12961-025-01415-8 PubMed PMID: 41131604; PubMed Central PMCID: PMC12551358.

[3] Tawfik EA, Tawfik AF, Alajmi AM, Badr MY, Al-jedai A, Almozain NH, et al. Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. Saudi Pharm J. 2022 Jan;30(1):28–38. doi: 10.1016/j.jsps.2021.12.002 PubMed PMID: 35145343; PubMed Central PMCID: PMC8802089.

[4] Li L, Li D, Goerzen A, Shi W (Stone). What and how do SMEs gain by going international? A longitudinal investigation of financial and intellectual resource growth. Journal of World Business. 2018 Dec 1;53(6):817–34. doi: 10.1016/j.jwb.2018.07.001

[5] Martins FS, Kollipara S, Sivadasu P, Yu M, Severino P, Souto E. The Innovation Paradox in Emerging Pharmaceutical Markets: Barriers and Opportunities for Sustainable Development. Pharm Res. 2025 Jun;42(6):1047–58. doi:10.1007/s11095-025-03856-w PubMed PMID: 40442394.

[6] Phan TH, Stachuletz R, Nguyen HTH. Export Decision and Credit Constraints under Institution Obstacles. Sustainability. 2022 May 6;14(9). doi:10.3390/su14095638

[7] Morton WA. Regulatory pathways to the market: an overview. Artif Organs. 1982 Nov;6(4):463–9. doi:10.1111/j.1525-1594. 1982.tb04146.x PubMed PMID: 6762190.

[8] Iheanachor N, Umukoro IO, David-West O. The role of product development practices on new product performance: Evidence from Nigeria’s financial services providers. Technol Forecast Soc Change. 2021 Mar; 164:120470. doi: 10.1016/j.techfore.2020.120470 PubMed PMID: 33664533; PubMed Central PMCID: PMC7893682.

[9] Dangy-Caye A, Mousset A, Kermad A, Bouché-Bazerolle L, Bujar M, De Lucia ML, et al. Harmonizing health: a global analysis of pharmaceutical regulatory activities by international regulatory organizations. Front Med (Lausanne). 2025 Sep 23; 12:1636269. doi:10.3389/fmed.2025.1636269 PubMed PMID: 41064519; PubMed Central PMCID: PMC12500574.

[10] Fonseca EM da, Shadlen KC, Achcar H de M. Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions. Research Policy. 2023 May 1;52(4):104739. doi: 10.1016/j.respol.2023.104739

[11] Liu J, Zhu H, Wang G. Multiple Pathways to Internationalization Performance in Chinese Plant-Based Food Enterprises: A Configurational Analysis Using fsQCA. Sustainability. 2026 Jun 8;18(12). doi:10.3390/su18125915

[12] Achmad F, Wiratmadja II. Organizational performance and competitive advantage in SMEs: The role of green innovation and knowledge management. Journal of Open Innovation: Technology, Market, and Complexity. 2025 Jun 1;11(2):100532. doi: 10.1016/j.joitmc.2025.100532

[13] Umaru OT, Adeyemi AS, Aderonmu O, Bhangu BS, Dhaliwal HS, Lim H, et al. Global Pharmaceutical Regulation: Comparative Frameworks and Operations. Pharmacy (Basel). 2026 Mar 18;14(2):50. doi:10.3390/pharmacy14020050 PubMed PMID: 41874058; PubMed Central PMCID: PMC13010624.

[14] TRS 1033 - Annex 10: Good reliance practices in the regulation of medical products: high level principles and considerations [Internet]. [cited 2026 Jun 10]. Available from: https://www.who.int/publications/m/item/annex-10-trs-1033

[15] Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa. South Med Rev. 2012 Jul 23;5(1):31–7. PubMed PMID: 23093897; PubMed Central PMCID: PMC3471191.

[16] Vieira D, Duarte J, Vieira P, Gonçalves MBS, Figueiras A, Lohani A, et al. Regulation and Safety of Cosmetics: Pre- and Post-Market Considerations for Adverse Events and Environmental Impacts. Cosmetics. 2024 Oct 23;11(6). doi:10.3390/cosmetics11060184

[17] Al Azawei A, Loughrey K, Surim K, Connolly ME, Naughton BD. The management of good manufacturing practice (GMP) inspections: a scoping review of the evidence. Front Med (Lausanne). 12:1687864. doi:10.3389/fmed.2025.1687864 PubMed PMID: 41306493; PubMed Central PMCID: PMC12645793.

[18] Reis ME, Bettencourt A, Ribeiro HM. The regulatory challenges of innovative customized combination products. Front Med (Lausanne). 2022 Jul 22; 9:821094. doi:10.3389/fmed.2022.821094 PubMed PMID: 35935795; PubMed Central PMCID: PMC9354569.

[19] Karklina-Admine S, Cevers A, Kovalenko A, Auzins A. Challenges for Customs Risk Management Today: A Literature Review. Journal of Risk and Financial Management. 2024 Jul 24;17(8). doi:10.3390/jrfm17080321

[20] Hassen HK, Mekasha YT, Tegegne AA, Ozalp Y. A narrative review on problems in product quality, regulatory system constraints, and the concept of quality by design as a solution for quality assurance of African medicines. Front Med (Lausanne). 2024 Oct 3; 11:1472495. doi:10.3389/fmed.2024.1472495 PubMed PMID: 39421861; PubMed Central PMCID: PMC11484627.

[21] Nwoke J. Regulatory Compliance and Risk Management in Pharmaceuticals and Healthcare. International Journal of Health Sciences. 2024 Sep 8;7(6):60–88. doi:10.47941/ijhs.2223

[22] Drinkwater S, Robinson C. The impact of customs and trade regulations on the operations of African firms. Journal of Business Research. 2023 Oct 1; 165:114046. doi: 10.1016/j.jbusres.2023.114046

[23] Bui AT, Pham TP, Pham LC, Ta TKV. Legal and financial constraints and firm growth: small and medium enterprises (SMEs) versus large enterprises. Heliyon. 2021 Dec 10;7(12): e08576. doi: 10.1016/j.heliyon. 2021.e08576 PubMed PMID: 34977406; PubMed Central PMCID: PMC8683731.

[24] Akang AU (mnim). REGULATORY COMPLIANCE AND ACCESS TO FINANCE: IMPLICATIONS FOR BUSINESS GROWTH IN DEVELOPING ECONOMIES. Sciental Journal of Education Humanities and Social Sciences. 2023;1(2):8–23. doi: 10.62536/sjehss.2023.v1.i2.pp8-23

[25] Kianpour M, Raza S. More than malware: unmasking the hidden risk of cybersecurity regulations. Int Cybersecur Law Rev. 2024 Mar 1;5(1):169–212. doi:10.1365/s43439-024-00111-7

[26] Mentzelou K, Chountalas PT, Kitsios FC, Magoutas AI, Dasaklis TK. Identifying and Modeling Barriers to Compliance with the NIS2 Directive: A DEMATEL Approach. Journal of Cybersecurity and Privacy. 2025 Nov 6;5(4). doi:10.3390/jcp5040097

[27] Pihwal K, Pawar N, Aamir S, Alam MS, Rathee V. A Comprehensive Review of Regulatory Requirements and Registration Process of Pharmaceutical Drug Products in CIS Countries. Applied Clinical Research, Clinical Trials and Regulatory Affairs. 7(3):162–76. doi:10.2174/2213476X07666200708105237

[28] Dinçkol D, Ozcan P, Zachariadis M. Regulatory standards and consequences for industry architecture: The case of UK Open Banking. Research Policy. 2023 Jul 1;52(6):104760. doi: 10.1016/j.respol.2023.104760

[29] Kgakatsi M, Galeboe OP, Molelekwa KK, Thango BA. The Impact of Big Data on SME Performance: A Systematic Review. Businesses. 2024 Nov 13;4(4):632–95. doi:10.3390/businesses4040038

[30] Mubarak Z, Abbas N, Hashmi FK, Shahbaz H, Bukhari NI. Industrial prospects on regulatory gaps and barriers in pharmaceutical exports and their counteraction: Local experiential with global implication. PLoS One. 2024 Jul 19;19(7): e0305989. doi: 10.1371/journal.pone.0305989 PubMed PMID: 39028685; PubMed Central PMCID: PMC11259304.

[31] Adomako S, Tran MD. Innovating against the odds? The impact of regulatory challenges on technology commercialization and product innovation performance. Technology in Society. 2026 Apr 1; 85:103214. doi: 10.1016/j.techsoc.2026.103214

[32] Alshahrani MA, Salam MA. The Role of Supply Chain Resilience on SMEs’ Performance: The Case of an Emerging Economy. Logistics. 2022 Jul 10;6(3). doi:10.3390/logistics6030047

[33] Kiani Mavi R, Kiani Mavi N, Hosseini Shekarabi SA, Pepper’s M, Arisian S. Supply Chain Resilience: A Common Weights Efficiency Analysis with Non-discretionary and Non-controllable Inputs. Glob J Flex Syst Manag. 2023 Dec 1;24(1):77–99. doi:10.1007/s40171-024-00380-5

[34] Prasanna R, Jayasundara J, Naradda Gamage SK, Ekanayake E, Rajapakshe P, Abeyrathne G. Sustainability of SMEs in the Competition: A Systemic Review on Technological Challenges and SME Performance. Journal of Open Innovation: Technology, Market, and Complexity. 2019 Dec 1;5(4):100. doi:10.3390/joitmc5040100

[35] Apooyin A. Risk management and compliance in a Globalized Economy: Navigating Regulatory Challenges and Strategic Adaptations. International Journal of Science and Research Archive. 2025;15(1):985–97. doi:10.30574/ijsra.2025.15.1.1098

[36] Burugulla JKR. Enhancing Regulatory Compliance in Finance through Big Data Analytics and AI Automation. Universal Journal of Finance and Economics. 2020 Dec;1(1):1–20. doi:10.31586/ujfe.2020.1335

[37] Muppalla A, Maddi BD, Maddi NV. Artificial Intelligence in Regulatory Compliance: Transforming Pharmaceutical and Healthcare Documentation. International Journal of Drug Regulatory Affairs. 2025 Jun 15;13(2):73–80. doi:10.22270/ijdra. v13i2.764

[38] Keelson SA, Cúg J, Amoah J, Petráková Z, Addo JO, Jibril AB. The Influence of Market Competition on SMEs’ Performance in Emerging Economies: Does Process Innovation Moderate the Relationship? Economies. 2024 Oct 21;12(11). doi:10.3390/economies12110282

[39] Jørgensen BN, Ma ZG. Impact of EU Regulations on AI Adoption in Smart City Solutions: A Review of Regulatory Barriers, Technological Challenges, and Societal Benefits. Information. 2025 Jul 2;16(7). doi:10.3390/info16070568

[40] Sitisara S, Jinarat S, Ngamsaard W, Suthikarnnarunai N. Revolutionizing Harmonized System (HS) Code Search with Semantic Search and Word Embeddings: Empowering Trade Classifications. Forum for Linguistic Studies. 2025 Sep 25;7(10):356–71. doi:10.30564/fls. v7i10.10822

[41] Gunningham N. Regulating Small and Medium Sized Enterprises. J Environmental Law. 2002 Jan 1;14(1):3–32. doi:10.1093/jel/14.1.3

[42] Khiewngamdee C, Chanaim S. The Role of Institutional and Innovation Ecosystem in Moderating the Impact of Green Practices on Export Performance: Evidence from European Countries. Sustainability. 2025 Oct 14;17(20). doi:10.3390/su17209146

[43] Limited (PPL) PP. Regulatory Challenges in Pharma Development Across US, UK & Canada [Internet]. [cited 2026 Jun 10]. Available from: https://www.piramalpharma.com/news-and-media/blogs/regulatory-challenges-in-pharma-development-across-us-uk-canada

[44] Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon. 2024 Feb 15;10(4):e26297. doi: 10.1016/j.heliyon. 2024.e26297 PubMed PMID: 38384518; PubMed Central PMCID: PMC10879008.

[45] Verbeke A. The future of international business strategy research. International Business Review. 2026 Aug 1;35(4):102596. doi: 10.1016/j.ibusrev.2026.102596

@article{1719065,
      author = {Oluchi Beatrice Aneke, Dorcas Okayo Okoroafor, Patricia Ebere Iwerumoh},
      title = {Good Products, Closed Doors: The Regulatory Market Entry Crisis Facing U.S. Pharmaceutical and Biomedical SMEs},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {12},
      pages = {2669-2684},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1719065.pdf},
      abstract = {The United States remains a global leader in pharmaceutical and biomedical innovation, with small and medium-sized enterprises (SMEs) playing a critical role in developing advanced therapeutics, diagnostics, medical devices, and biotechnology solutions. Despite producing scientifically validated and globally competitive products, many of these firms struggle to achieve successful international market entry and sustained export growth. This article examines the regulatory market entry crisis facing U.S. pharmaceutical and biomedical SMEs, arguing that export underperformance is driven less by product quality and more by systemic regulatory barriers. Specifically, the paper explores how regulatory complexity, fragmented international approval systems, Harmonized System (HS) classification errors, and limited access to affordable compliance infrastructure constrain global market participation. While large pharmaceutical corporations possess dedicated regulatory affairs teams and extensive compliance resources, SMEs often lack the organizational capacity and financial resources necessary to navigate increasingly complex regulatory environments. The consequences extend beyond individual firms, limiting innovation commercialization, reducing export competitiveness, and weakening the global reach of U.S. biomedical innovation. The article further contends that these challenges represent not only a business concern but also a broader issue of national competitiveness, supply chain resilience, and economic security. To address this gap, the paper proposes the recognition of regulatory market entry strategy as a formal strategic discipline and advocates for scalable compliance solutions capable of improving export readiness among pharmaceutical and biomedical SMEs. Strengthening regulatory capabilities may enhance international market access, accelerate innovation diffusion, and reinforce the long-term competitiveness of the U.S. life sciences sector.},
      keywords = {Biomedical Exports, Compliance Infrastructure, HS Classification, Pharmaceutical SMEs, Regulatory Market Entry.},
      month = {June},
      doi = {https://doi.org/10.64388/IREV9I12-1719065}
  }